Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis

被引：51

作者：

Baker, William L. ^{[1
,2
]}

Silver, Dee ^{[3
]}

White, C. Michael ^{[1
,2
]}

Kluger, Jeffrey ^{[4
]}

Aberle, Jeffrey ^{[1
,2
]}

Patel, Aarti A. ^{[5
]}

Coleman, Craig I. ^{[1
,2
]}

机构：

[1] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA

[2] Hartford Hosp, Dept Drug Informat, Hartford, CT 06102 USA

[3] Scripps Mem Hosp, La Jolla, CA USA

[4] Hartford Hosp, Dept Med, Hartford, CT 06102 USA

[5] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

来源：

PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷 / 04期

关键词：

Parkinson's disease; Dopamine agonists; Non-ergot dopamine agonists; Meta-analysis; QUALITY STANDARDS SUBCOMMITTEE; VALVULAR HEART-DISEASE; DOUBLE-BLIND; LEVODOPA MONOTHERAPY; PRACTICE PARAMETER; EARLY COMBINATION; AMERICAN-ACADEMY; CLINICAL-TRIALS; FOLLOW-UP; BROMOCRIPTINE;

D O I：

10.1016/j.parkreldis.2008.07.004

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Our objective was to perform a meta-analysis of randomized controlled trials of dopamine agonists (DA) as monotherapy as well as adjunctive therapy for the early treatment of Parkinson's disease (PD). A systematic literature search was conducted through April 2007. Both efficacy and safety endpoints were evaluated. DA monotherapy showed superior efficacy but more frequent adverse events compared to placebo. In addition, DA demonstrated inferior efficacy to levodopa, but was associated with fewer motor complications. However, DAs were associated with a greater incidence of nuisance side effects, such as hallucinations, somnolence and dizziness. The use of DA is an effective treatment option for the treatment of early PD and appears especially useful among PD patients with wearing-off phenomenon or dyskinesias on levodopa; however it may result in more adverse events and higher withdrawal rates. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：287 / 294

页数：8

共 46 条

[1] Ropinirole for the treatment of early Parkinson's disease [J].

Adler, CH ;

Sethi, KD ;

Hauser, RA ;

Davis, TL ;

Hammerstad, JP ;

Bertoni, J ;

Taylor, RL ;

SanchezRamos, J ;

OBrien, CF .

NEUROLOGY, 1997, 49 (02) :393-399

[2] Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease [J].

Allain, H ;

Destée, A ;

Petit, H ;

Patay, M ;

Schück, S ;

Bentué-Ferrer, D ;

Le Cavorzin, P .

EUROPEAN NEUROLOGY, 2000, 44 (01) :22-30

[3]

[Anonymous], 2003, COCHRANE DATABASE SY

[4] LONG-TERM DOUBLE MASKED TRIAL OF EARLY TREATMENT WITH L-DOPA PLUS BROMOCRIPTINE VERSUS L-DOPA ALONE IN PARKINSONS-DISEASE - INTERIM RESULTS [J].

BAKHEIT, AMO ;

HENDERSON, LM ;

MOORE, AP ;

SIMPSON, JA ;

THOMAS, M .

EUROPEAN NEUROLOGY, 1990, 30 (02) :108-111

[5] Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients:: results of a multicentre, randomized, double-blind, placebo-controlled study [J].

Bergamasco, B ;

Frattola, L ;

Muratorio, A ;

Piccoli, F ;

Mailland, F ;

Parnetti, L .

ACTA NEUROLOGICA SCANDINAVICA, 2000, 101 (06) :372-380

[6] The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease - Final results of a 5-year, double-blind, Levodopa-controlled study [J].

Bracco, F ;

Battaglia, A ;

Chouza, C ;

Dupont, E ;

Gershanik, O ;

Masso, JFM ;

Montastruc, JL .

CNS DRUGS, 2004, 18 (11) :733-746

[7]

Brooks DJ, 1998, CLIN NEUROPHARMACOL, V21, P101

[8] Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study [J].

Caraceni, T ;

Musicco, M .

PARKINSONISM & RELATED DISORDERS, 2001, 7 (02) :107-114

[9] METAANALYSIS IN CLINICAL-TRIALS [J].

DERSIMONIAN, R ;

LAIRD, N .

CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188

[10] Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis [J].

Duval, S ;

Tweedie, R .

BIOMETRICS, 2000, 56 (02) :455-463

← 1 2 3 4 5 →